Eric J. Small

68.4k total citations · 11 hit papers
613 papers, 35.7k citations indexed

About

Eric J. Small is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Eric J. Small has authored 613 papers receiving a total of 35.7k indexed citations (citations by other indexed papers that have themselves been cited), including 494 papers in Pulmonary and Respiratory Medicine, 232 papers in Oncology and 158 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Eric J. Small's work include Prostate Cancer Treatment and Research (440 papers), Radiopharmaceutical Chemistry and Applications (149 papers) and Prostate Cancer Diagnosis and Treatment (134 papers). Eric J. Small is often cited by papers focused on Prostate Cancer Treatment and Research (440 papers), Radiopharmaceutical Chemistry and Applications (149 papers) and Prostate Cancer Diagnosis and Treatment (134 papers). Eric J. Small collaborates with scholars based in United States, Canada and United Kingdom. Eric J. Small's co-authors include Susan Halabi, Philip W. Kantoff, Celestia S. Higano, Brian I. Rini, Paul F. Schellhammer, Nicholas J. Vogelzang, Mark W. Frohlich, Charles H. Redfern, Robert Dreicer and Maha Hussain and has published in prestigious journals such as New England Journal of Medicine, JAMA and Nature Communications.

In The Last Decade

Eric J. Small

595 papers receiving 34.9k citations

Hit Papers

Sipuleucel-T Immunotherapy for Castration-Resistant Prost... 2003 2026 2010 2018 2010 2004 2008 2018 2006 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
    2010 4.1k citations Philip W. Kantoff, Celestia S. Higano et al. profile →
  2. Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer
    2004 2.9k citations Daniel P. Petrylak, Primo N. Lara et al. profile →
  3. Design and End Points of Clinical Trials for Patients With Progressive Prostate Cancer and Castrate Levels of Testosterone: Recommendations of the Prostate Cancer Clinical Trials Working Group
    2008 1.7k citations Susan Halabi, Michael J. Morris et al. Journal of Clinical Oncology profile →
  4. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer
    2018 868 citations Matthew R. Smith, Fred Saad et al. profile →
  5. Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer
    2006 840 citations Eric J. Small, Paul F. Schellhammer et al. Journal of Clinical Oncology profile →
  6. Bevacizumab Plus Interferon Alfa Compared With Interferon Alfa Monotherapy in Patients With Metastatic Renal Cell Carcinoma: CALGB 90206
    2008 707 citations Brian I. Rini, Susan Halabi et al. Journal of Clinical Oncology profile →
  7. Integrated data from 2 randomized, double‐blind, placebo‐controlled, phase 3 trials of active cellular immunotherapy with sipuleucel‐T in advanced prostate cancer
    2009 605 citations Celestia S. Higano, Paul F. Schellhammer et al. profile →
  8. Prognostic Model for Predicting Survival in Men With Hormone-Refractory Metastatic Prostate Cancer
    2003 541 citations Susan Halabi, Eric J. Small et al. Journal of Clinical Oncology profile →
  9. Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial
    2017 507 citations Toni K. Choueiri, Susan Halabi et al. Journal of Clinical Oncology profile →
  10. Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer
    2015 367 citations Arun Azad, Stanislav Volik et al. Clinical Cancer Research profile →
  11. A Pilot Trial of CTLA-4 Blockade with Human Anti-CTLA-4 in Patients with Hormone-Refractory Prostate Cancer
    2007 323 citations Eric J. Small, Brian I. Rini et al. Clinical Cancer Research profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Eric J. Small United States 86 24.2k 14.3k 8.9k 8.3k 6.8k 613 35.7k
Celestia S. Higano United States 68 16.6k 0.7× 10.3k 0.7× 7.0k 0.8× 5.8k 0.7× 5.4k 0.8× 386 27.1k
Nicholas J. Vogelzang United States 89 22.7k 0.9× 17.2k 1.2× 8.4k 0.9× 6.5k 0.8× 4.1k 0.6× 701 41.8k
Neal D. Shore United States 59 17.0k 0.7× 9.5k 0.7× 4.9k 0.5× 4.8k 0.6× 3.2k 0.5× 768 25.3k
Johann S. de Bono United Kingdom 108 29.0k 1.2× 22.3k 1.6× 18.9k 2.1× 14.1k 1.7× 3.6k 0.5× 1.0k 53.2k
Fred Saad Canada 83 23.9k 1.0× 15.4k 1.1× 7.6k 0.9× 6.9k 0.8× 1.5k 0.2× 1.2k 36.7k
Stéphane Oudard France 73 27.5k 1.1× 13.8k 1.0× 16.5k 1.9× 12.0k 1.4× 2.4k 0.4× 618 38.8k
Martin Gleave Canada 98 15.8k 0.7× 9.0k 0.6× 15.6k 1.8× 8.7k 1.0× 2.4k 0.4× 680 32.4k
Mario A. Eisenberger United States 74 21.3k 0.9× 8.5k 0.6× 5.1k 0.6× 6.4k 0.8× 1.1k 0.2× 380 27.2k
Kim N. Canada 56 20.4k 0.8× 8.6k 0.6× 6.7k 0.8× 8.0k 1.0× 1.1k 0.2× 369 26.1k
Cora N. Sternberg United States 76 21.0k 0.9× 12.1k 0.8× 7.6k 0.8× 6.6k 0.8× 1.5k 0.2× 583 34.5k

Countries citing papers authored by Eric J. Small

Since Specialization
Citations

This map shows the geographic impact of Eric J. Small's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Small with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Small more than expected).

Fields of papers citing papers by Eric J. Small

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Eric J. Small. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Small. The network helps show where Eric J. Small may publish in the future.

Co-authorship network of co-authors of Eric J. Small

This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Small. A scholar is included among the top collaborators of Eric J. Small based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eric J. Small. Eric J. Small is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, William S., Amir Ashraf‐Ganjouei, Alon Witztum, et al.. (2025). Utility of metastasis-directed radiotherapy with and without hormonal therapy in management of oligometastatic prostate cancer. JNCI Cancer Spectrum. 9(6).
2.
3.
Saad, Fred, Eric J. Small, Felix Y. Feng, et al.. (2021). Deep Prostate-specific Antigen Response following Addition of Apalutamide to Ongoing Androgen Deprivation Therapy and Long-term Clinical Benefit in SPARTAN. European Urology. 81(2). 184–192. 35 indexed citations
4.
Aggarwal, Rahul, Michael T. Schweizer, David M. Nanus, et al.. (2020). A Phase Ib/IIa Study of the Pan-BET Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer. Clinical Cancer Research. 26(20). 5338–5347. 97 indexed citations
5.
Fendler, Wolfgang P., Manuel Weber, Amir Iravani, et al.. (2019). Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 25(24). 7448–7454. 183 indexed citations
6.
Aggarwal, Rahul, David A. Quigley, Jiaoti Huang, et al.. (2019). Whole-Genome and Transcriptional Analysis of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer Demonstrates Intraclass Heterogeneity. Molecular Cancer Research. 17(6). 1235–1240. 40 indexed citations
7.
Antonarakis, Emmanuel S., Eric J. Small, Daniel P. Petrylak, et al.. (2018). Antigen-Specific CD8 Lytic Phenotype Induced by Sipuleucel-T in Hormone-Sensitive or Castration-Resistant Prostate Cancer and Association with Overall Survival. Clinical Cancer Research. 24(19). 4662–4671. 26 indexed citations
8.
Aggarwal, Rahul, Spencer C. Behr, Pamela L. Paris, et al.. (2017). Real-Time Transferrin-Based PET Detects MYC-Positive Prostate Cancer. Molecular Cancer Research. 15(9). 1221–1229. 12 indexed citations
9.
Choueiri, Toni K., Susan Halabi, Ben L. Sanford, et al.. (2017). Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial. Journal of Clinical Oncology. 35(6). 591–597. 507 indexed citations breakdown →
10.
Wei, Xiao X., Serena S. Kwek, Jera Lewis, et al.. (2016). Systemic GM-CSF Recruits Effector T Cells into the Tumor Microenvironment in Localized Prostate Cancer. Cancer Immunology Research. 4(11). 948–958. 30 indexed citations
11.
Small, Eric J., Raymond S. Lance, Thomas A. Gardner, et al.. (2015). A Randomized Phase II Trial of Sipuleucel-T with Concurrent versus Sequential Abiraterone Acetate plus Prednisone in Metastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 21(17). 3862–3869. 61 indexed citations
12.
Kwek, Serena S., Jera Lewis, Li Zhang, et al.. (2015). Preexisting Levels of CD4 T Cells Expressing PD-1 Are Related to Overall Survival in Prostate Cancer Patients Treated with Ipilimumab. Cancer Immunology Research. 3(9). 1008–1016. 50 indexed citations
13.
GuhaThakurta, Debraj, Nadeem A. Sheikh, Li-Qun Fan, et al.. (2015). Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome. Clinical Cancer Research. 21(16). 3619–3630. 101 indexed citations
14.
Azad, Arun, Stanislav Volik, Alexander W. Wyatt, et al.. (2015). Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer. Clinical Cancer Research. 21(10). 2315–2324. 367 indexed citations breakdown →
15.
McNeel, Douglas G., Thomas A. Gardner, Celestia S. Higano, et al.. (2014). A Transient Increase in Eosinophils Is Associated with Prolonged Survival in Men with Metastatic Castration-Resistant Prostate Cancer Who Receive Sipuleucel-T. Cancer Immunology Research. 2(10). 988–999. 44 indexed citations
16.
Kim, Won, Li Zhang, John H. Wilton, et al.. (2014). Sequential Use of the Androgen Synthesis Inhibitors Ketoconazole and Abiraterone Acetate in Castration-Resistant Prostate Cancer and the Predictive Value of Circulating Androgens. Clinical Cancer Research. 20(24). 6269–6276. 31 indexed citations
17.
Kavanagh, Brian D., Shaun O’Brien, David Lee, et al.. (2008). CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood. 112(4). 1175–1183. 201 indexed citations
18.
Small, Eric J., Paul F. Schellhammer, Celestia S. Higano, et al.. (2006). Placebo-Controlled Phase III Trial of Immunologic Therapy with Sipuleucel-T (APC8015) in Patients with Metastatic, Asymptomatic Hormone Refractory Prostate Cancer. Journal of Clinical Oncology. 24(19). 3089–3094. 840 indexed citations breakdown →
19.
Small, Eric J., et al.. (2006). Sipuleucel-T (APC8015) for prostate cancer. Expert Review of Anticancer Therapy. 6(9). 1163–1167. 41 indexed citations
20.
Reese, David, Eric J. Small, Gregg Magrane, et al.. (2001). HER2 Protein Expression and Gene Amplification in Androgen-Independent Prostate Cancer. American Journal of Clinical Pathology. 116(2). 234–239. 63 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Celestia S. Higano Breakdown of academic impact, for papers by Nicholas J. Vogelzang Breakdown of academic impact, for papers by Neal D. Shore Breakdown of academic impact, for papers by Johann S. de Bono Breakdown of academic impact, for papers by Fred Saad Breakdown of academic impact, for papers by Stéphane Oudard Breakdown of academic impact, for papers by Martin Gleave Breakdown of academic impact, for papers by Mario A. Eisenberger Breakdown of academic impact, for papers by Kim N. Breakdown of academic impact, for papers by Cora N. Sternberg
Rankless by CCL
2026